Company / Capital Expenditures
Tarsus Pharmaceuticals, Inc. Capital Expenditures History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$9.9M
FY2025
5-year range
$586.0K / $9.9M
FY2021-FY2025
Trend
+529.2%
vs FY2024
Sector context
#58 of 194
Health Care
What the data says
Capital Expenditures changed +529% YoY in FY2025, a notable deviation from the 6-year average annual change of +146%.
Based on SEC 10-K filings.
$10M in FY2025 with a 5-year CAGR of +84.9%.
Improved from $2M to $10M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +156.2%
- 5-Year CAGR
- +84.9%
- 10-Year CAGR
- -
Sector benchmark
#58 of 194 in Health CareTop 30% of 194This company $9.9M Sector average $117.5M
▼
-91.6% below sector average
Key checks
Key Insights
- Tarsus Pharmaceuticals, Inc.'s capital expenditures has grown for 3 consecutive years.
- 5-year CAGR of +84.9%, indicating consistent growth.
- In FY2025, capital expenditures increased 529.2% year-over-year.
- Ranks #58 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.9M | +529.2% |
| FY2024 | $1.6M | +4.3% |
| FY2023 | $1.5M | +156.3% |
| FY2022 | $586.0K | +0.0% |
| FY2021 | $586.0K | +28.5% |
| FY2020 | $456.0K | +160.6% |
| FY2019 | $175.0K | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026